GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Momenta Pharmaceuticals Inc (NAS:MNTA) » Definitions » Gross Profit

Momenta Pharmaceuticals (Momenta Pharmaceuticals) Gross Profit : $-127.42 Mil (TTM As of Jun. 2020)


View and export this data going back to 2004. Start your Free Trial

What is Momenta Pharmaceuticals Gross Profit?

Momenta Pharmaceuticals's gross profit for the three months ended in Jun. 2020 was $-32.23 Mil. Momenta Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Jun. 2020 was $-127.42 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Momenta Pharmaceuticals's gross profit for the three months ended in Jun. 2020 was $-32.23 Mil. Momenta Pharmaceuticals's Revenue for the three months ended in Jun. 2020 was $6.61 Mil. Therefore, Momenta Pharmaceuticals's Gross Margin % for the quarter that ended in Jun. 2020 was -487.62%.

Momenta Pharmaceuticals had a gross margin of -487.62% for the quarter that ended in Jun. 2020 => No sustainable competitive advantage

During the past 13 years, the highest Gross Margin % of Momenta Pharmaceuticals was 77.16%. The lowest was -505.59%. And the median was -33.14%.

Warning Sign:

Momenta Pharmaceuticals Inc gross margin has been in long term decline. The average rate of decline per year is -29.5%.


Momenta Pharmaceuticals Gross Profit Historical Data

The historical data trend for Momenta Pharmaceuticals's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Momenta Pharmaceuticals Gross Profit Chart

Momenta Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only -36.38 -10.26 -10.34 -48.42 -120.67

Momenta Pharmaceuticals Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -26.95 -39.71 -30.15 -25.32 -32.23

Competitive Comparison of Momenta Pharmaceuticals's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Momenta Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Momenta Pharmaceuticals's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Momenta Pharmaceuticals's Gross Profit distribution charts can be found below:

* The bar in red indicates where Momenta Pharmaceuticals's Gross Profit falls into.



Momenta Pharmaceuticals Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Momenta Pharmaceuticals's Gross Profit for the fiscal year that ended in Dec. 2019 is calculated as

Gross Profit (A: Dec. 2019 )=Revenue - Cost of Goods Sold
=23.868 - 144.542
=-120.67

Momenta Pharmaceuticals's Gross Profit for the quarter that ended in Jun. 2020 is calculated as

Gross Profit (Q: Jun. 2020 )=Revenue - Cost of Goods Sold
=6.61 - 38.842
=-32.23

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-127.42 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Momenta Pharmaceuticals's Gross Margin % for the quarter that ended in Jun. 2020 is calculated as

Gross Margin % (Q: Jun. 2020 )=Gross Profit (Q: Jun. 2020 ) / Revenue (Q: Jun. 2020 )
=(Revenue - Cost of Goods Sold) / Revenue
=-32.23 / 6.61
=-487.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Momenta Pharmaceuticals  (NAS:MNTA) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Momenta Pharmaceuticals had a gross margin of -487.62% for the quarter that ended in Jun. 2020 => No sustainable competitive advantage


Momenta Pharmaceuticals Gross Profit Related Terms

Thank you for viewing the detailed overview of Momenta Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Momenta Pharmaceuticals (Momenta Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
301 Binney Street, Cambridge, MA, USA, 02142
Momenta is a biotechnology company focused on the characterization and development of innovative drugs in autoimmune diseases. Its legacy business includes complex generic versions of MS drug Copaxone and anticoagulant Lovenox, and it receives royalties for these products through a partnership with Novartis. While a biosimilar version of Eylea is in the pipeline, Momenta terminated future development in generics/biosimilars in 2018. Several innovative drugs, including nipocalimab, M254, and M230, are in development to treat rare autoimmune diseases.
Executives
Bruce Downey director
Alejandra Carvajal officer: Chief Legal Officer C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
Jose-carlos Gutierrez-ramos director C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Georges Gemayel director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Elizabeth Stoner director C/O MOMENTA PHARMACEUTICALS, INC. 675 WEST KENDALL STREET CAMBRIDGE MA 02142
Santiago Arroyo officer: SVP, Chief Medical Officer C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Young Kwon officer: Chief Financial & Bus. Officer C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Ian Fier officer: Chief Mfg and Program Officer C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Jo Ann Beltramello officer: Chief HR and Inf. Officer C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Jane F Barlow director 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Anthony M. Manning officer: Chief Scientific Officer C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Donna Roy Grogan director 1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633
Agnieszka Cieplinska officer: Chief Accounting Officer (PAO) C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Craig A Wheeler director, officer: President & CEO

Momenta Pharmaceuticals (Momenta Pharmaceuticals) Headlines

From GuruFocus

Momenta Pharmaceuticals Announces CFO Transition

By Marketwired Marketwired 01-03-2020

Momenta Enters Definitive Agreement with Johnson & Johnson

By Marketwired Marketwired 08-19-2020